Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

952results about How to "Improved prognosis" patented technology

Medical device with coating that promotes cell adherence and differentiation

Compositions and methods are provided for producing a medical device such as a stent, a stent graft, a synthetic vascular graft, heart valves, coated with a biocompatible matrix which incorporates antibodies, antibody fragments, or small molecules, which recognize, bind to and / or interact with a progenitor cell surface antigen to immobilize the cells at the surface of the device. The coating on the device can also contain a compound or growth factor for promoting the progenitor endothelial cell to accelerate adherence, growth and differentiation of the bound cells into mature and functional endothelial cells on the surface of the device to prevent intimal hyperplasia. Methods for preparing such medical devices, compositions, and methods for treating a mammal with vascular disease such as restenosis, artherosclerosis or other types of vessel obstructions are disclosed.
Owner:ORBUSNEICH MEDICAL PTE LTD

Cage having spike

ActiveUS20150127107A1Improve prognosisReduce possibilityInternal osteosythesisJoint implantsCervical disc diseasesVertebra
The present invention relates to a cage which is inserted between vertebral bodies of a cervical vertebra or spine during an operation for treating a cervical disc disease, myelosis, or fracture of the cervical vertebra or spine, and more particularly, to a cage with spikes, including upper and lower spikes which are attached to a clip inserted into a main body of the cage, unfolded upward and downward from the main body, and locked to vertebral bodies of a cervical vertebra or spine positioned at the top and bottom of the cage such that the cage is fixed and locked between the vertebral bodies.
Owner:LDR MEDICAL

Signatures of ER status in breast cancer

The invention relates to the identification and use of gene expression profiles, or patterns, suitable for identification of populations that are positive and negative for estrogen receptor expression. The gene expression profiles may be embodied in nucleic acid expression, protein expression, or other expression formats, and may be used in the study and / or diagnosis of cells and tissue in breast cancer as well as for the study and / or determination of prognosis of a patient, including breast cancer survival.
Owner:ACTURUS BIOSCI INC +1

Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in lung cancer cells

The present invention describes polynucleotides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., lung cell lines, to treatment with compounds that interact with and modulate, e.g., inhibit, protein tyrosine kinases, such as, for example, members of the Src family of tyrosine kinases, e.g., Src, Fgr, Fyn, Yes, Blk, Hck, Lck and Lyn, as well as other protein tyrosine kinases, including, Bcr-abl, Jak, PDGFR, c-kit and Ephr. These polynucleotides have been shown, through a weighted voting cross validation program, to have utility in predicting the resistance and sensitivity of lung cell lines to the compounds. The expression level of some polynucleotides is regulated by treatment with a particular protein tyrosine kinase inhibitor compound, thus indicating that these polynucleotides are involved in the protein tyrosine kinase signal transduction pathway, e.g., Src tyrosine kinase. Such polynucleotides, whose expression levels correlate highly with drug sensitivity or resistance and which are modulated by treatment with the compounds, comprise polynucleotide predictor or marker sets useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas, e.g., lung cancer, in which signaling through the protein tyrosine kinase pathway, such as the Src tyrosine kinase pathway, is involved with the disease process.
Owner:BRISTOL MYERS SQUIBB CO

Integrated Multimodality Intravascular Imaging System that Combines Optical Coherence Tomography, Ultrasound Imaging, and Acoustic Radiation Force Optical Coherence Elastography

A method of using an integrated intraluminal imaging system includes an optical coherence tomography interferometer (OCT), an ultrasound subsystem (US) and a phase resolved acoustic radiation force optical coherence elastography subsystem (PR-RAF-OCE). The steps include performing OCT to generate a returned optical signal, performing US imaging to generate a returned ultrasound signal, performing PR-ARF-OCE to generate a returned PR-ARF-OCE signal by generating a amplitude modulated ultrasound beam or chirped amplitude modulated ultrasound beam to frequency sweep the acoustic radiation force, measuring the ARF induced tissue displacement using phase resolved OCT method, and the frequency dependence of the PR-ARF-OCE signal, processing the returned optical signal, the returned ultrasound signal and the measured frequency dependence of the returned PR-ARF-OCE optical coherence elastographic signal to quantitatively measure the mechanical properties of the identified tissues with both spectral and spatial resolution using enhanced materials response at mechanically resonant frequencies to distinguish tissues with varying stiffness, to identify tissues with different biomechanical properties and to measure structural and mechanical properties simultaneously.
Owner:RGT UNIV OF CALIFORNIA

Cancer Markers

InactiveUS20080188405A1Prognosis is dramatically affected by Numb statusImproved prognosisPeptide/protein ingredientsMicrobiological testing/measurementImmunologyCancer marker
The invention related to methods of diagnosis and prognosis of cancer, the methods comprising determining the level of one or more gene products. In addition, the invention relates to modulators of the gene products for use in treatment of cancer. The genes include EIA-induced genes and Numb.
Owner:IFOM FOND INST FIRC DI ONCOLOGIA MOLECOLARE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products